Navigation Links
NUCRYST Announces Completion of Amalgamation
Date:2/8/2010

PRINCETON, NJ, Feb. 8 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ("Nucryst") (TSX:NCS / NASDAQ:NCST) today is pleased to announce the completion of the previously announced amalgamation (the "Amalgamation") of Nucryst with 1499642 Alberta Ltd. ("1499642"), a wholly-owned subsidiary of the Westaim Corporation ("Westaim"), pursuant to an Amalgamation Agreement dated as of November 10, 2009, as amended (the "Amalgamation Agreement"). The resolution approving the Amalgamation was approved at the Special Meeting of Shareholders reconvened and concluded on February 8, 2010 and the Amalgamation was effected by the filing of Articles of Amalgamation thereafter.

Pursuant to the Amalgamation Agreement, NUCRYST was amalgamated with 1499642 to form Westaim Holdings Limited ("Amalco"), a wholly-owned subsidiary of Westaim. Amalco will continue as the surviving company and will succeed to and assume all the rights and obligations of Nucryst.

Further, pursuant to the Amalgamation Agreement, each issued and outstanding NUCRYST share, other than those held by Westaim, was converted into one series 1 preferred share of Amalco, which is redeemable for cash consideration of U.S.$1.77. Each issued and outstanding NUCRYST share held by Westaim was converted into one common share of Amalco. With the Amalgamation completed, Amalco intends to delist Nucryst shares from the TSX and NASDAQ stock exchanges and remove Nucryst shares from registration under applicable securities laws.

In order to receive the redemption consideration of U.S.$1.77 per share, shareholders should follow the instructions set forth under "Information Regarding the Amalgamation-Redemption Procedure" in the Notice and Information Circular dated November 25, 2009 previously delivered to shareholders in connection with the Special Meeting of Shareholders and filed with securities authorities in Canada on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission on December 1, 2009 as Exhibit (a)(1) to the Schedule 13E-3 Transaction Statement filed by Nucryst, Westaim and 1499642. NUCRYST shares may be redeemed at any time prior to the fifth anniversary of the Amalgamation.

The Amalgamation follows the sale by Nucryst of substantially all of its assets pursuant to an asset purchase agreement dated November 10, 2009, as amended, among Nucryst, NUCRYST Pharmaceuticals Inc., Smith & Nephew Inc. and Smith & Nephew (Overseas) Limited.

This news release is for information purposes only and is not a substitute for the definitive agreements or other disclosures provided in the Information Circular and supplements provided to shareholders in relation to the Amalgamation.

About NUCRYST Pharmaceuticals Corp.

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) sold its Acticoat business, constituting substantially all of its assets, on December 22, 2009. Following completion of the sale and prior to the completion of the Amalgamation, the Company consisted primarily of cash and short-term investments and no longer had any operating income.

This news release contains forward-looking statements within the meaning of securities legislation in the United States and Canada (collectively "forward-looking statements"). Forward-looking statements in this news release include, but are not limited to, statements regarding actions to be taken after completion of the Amalgamation such as the delisting and deregistration of Nucryst shares. With respect to the forward-looking statements contained in this news release, readers are cautioned that numerous risks, uncertainties and other factors could cause actual results or events to differ materially from those indicated in these statements including, but not limited to the ability to satisfy regulatory and stock exchange standards and requirements to complete the delisting from NASDAQ and TSX and the deregistration under applicable securities laws. Although the prior sentence attempts to identify the important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements in this release, there may be other factors that cause actual results or events to differ from those expressed or implied in forward looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST and Amalco disclaim any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.

SOURCE NUCRYST Pharmaceuticals Corp.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. NUCRYST Receives Deficiency Notice from NASDAQ
11. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: